Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

Sep 08, 2020 16:46 JST

Source: Aptorum Group Limited

HONG KONG, Sep 08, 2020 - (ACN Newswire) - Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the "BEAM Alliance") as full member.

The BEAM Alliance is a network of approximately 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance ("AMR"), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents, and medical devices, including in-vitro diagnostics.

"We are pleased to join the BEAM Alliance and strengthen our European network with the AMR community. The aims of the alliance and the pharmaceutical community are particularly synergistic with one of our core focus in infectious disease research, culminating the development of our ALS-4 and ALS-2/3 programs, to address global antimicrobial resistance against deadly bacteria such as methicillin-resistant staphylococcus aureus ("MRSA") and others. Being a part of the BEAM Alliance will further facilitate the exchange of information and potential establishment of collaborating partners within this AMR field and we look forward to contributing our efforts for global preparedness against AMR," said Mr. Darren Lui, President and Executive Director of Aptorum Group.

About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

For further general presentation, please visit: https://ir.aptorumgroup.com/static-files/ca36cc65-6f23-4105-895e-f5f234ecca1e

About the BEAM Alliance
BEAM represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much-needed innovation.

For more information about BEAM Alliance, please visit https://beam-alliance.eu/

Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorite des Marches Financiers visa n20-352 on 16 July 2020.

As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n2019/980 of 14 March 2019 and n2019/979 of 14 March 2019.

This press release is provided "as is" without any representation or warranty of any kind.

Contacts
Investor relations
Aptorum Group Limited
Investor Relations Department:
Tel: +44 020 80929299
Email: investor.relations@aptorumgroup.com

Redchip - Financial Communications United States
Investor relations
Dave Gentry
dave@redchip.com
+1 407 491 4498

Actifin - Financial Communications Europe
Investor relations
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22

Source: Aptorum Group Limited
Sectors: Daily Finance, Daily News, BioTech